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Abstract: One hundred liver fine-needle
aspiration cytology (FNAC) specimens
obtained from 42 patients with hepatocellular
carcinomas (HCC), 38 patients with
metastatic adenocarcinomas (MAC) and 20
patients with non-malignant liver disease
(control group) were studied.
Liver
specimens
were
stained
with
an
immunoperoxidase
method
using
a
monoclonal antibody to Ki-67 (MIB1).
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Ki-67 Antigen Expression in Hepatocellular Carcinoma,
Metastatic Adenocarcinoma and Normal Hepatocytes

Ki-67 antigen was visualised in cold acetone,
and a fresh liver needle aspiration cytology
specimen using antibodies was used to

Introduction
Established prognostic factors in hepatocellular
carcinomas (HCC) are: stage, tumor size, capsule
formation, capsule invasion, number of tumor nodules,
histologic subtype, mitotic index, differentiation, presence
of cirrhosis in patient, AFP level in serum, level of plazma
des-γ-carboxy prothrombin, tumor thrombus in the
portal vein, intrahepatic metastasis, and the proliferation
potential of tumor (1-8). In order to find out the
proliferation potential of tumor, proliferating cell nuclear
antigen (PCNA) (4-7) and p53 (9) were frequently used
with overexpression histologic slides and cytologic
materials, but because of some difficulties in applying it
to tissue, Ki-67 was used less frequently (10-14).
The current study is composed of two parts and has
two aims. One is to establish whether the Ki-67 labeling
index (LI) of liver fine-needle aspiration cytology (FNAC)
is a discriminating factor between HCC (42 cases),
metastatic adenocarcinoma (MAC) (38 cases) and the
control group (20 cases) or not. The other aim is to
establish the relationship between Ki-67 LI in HCC cases
and prognostic factors.

Materials and Methods
FNAC was performed by a clinician using Computed
Tomography (CT) or ultrasound guidance with a 22-

identify proliferating hepatocytes. In this
study it was examined that; if there is a
difference between the groups in terms of Ki67 positivity and degree of differentiation of
tumor and the relationship there in.
The Ki-67 labeling index (LI) of HCC cases
was significantly different from the other two
groups (p < 0.01). In additions, the numbers
of hepatocytes positive for Ki-67 has a good
correlation with the degree of differentiation
of HCC (t = 2.96, p < 0.01).
Key Words: Hepatocellular carcinoma, Ki-67
antigen, fine-needle aspiration, cytology

gauge spinal needle. The aspirated material was
immediately smeared onto between 4-20 glass slides. The
cellular slides are selected by direct visual inspection for
routinely examination and 2 of these are chosen for
immunocytologic examination. These slides are fixed in
cold acetone. The air-dried smears were stained with
May-Grunwald-Giemsa (MGG) stain.
Fine-needle aspiration from 42 HCC, 38 MAC cases
and 20 benign lesions were re-examined. The diagnosis
was confirmed by tissue examination (28 patients;
66.6%), or by clinical and laboratory findings alone in
HCC patients. All of the patients who had metastatic liver
lesions were eventually proven to have hepatic
malignancy following at subsequent tissue biopsy. There
was no malignancy in the reactive group.
The cellular structure of HCC cases was categorised
under three headings. These were well-differentiated cell
type (WDCT), pleomorphic large cell type (PLCT), and
poorly differentiated cell type (PDCT).
For the immunocytochemical stain, Ki-67 antigen was
applied to 100 liver FNAC, which included 42 HCC cases,
38 MAC cases and 20 non-neoplastic control cases.
The samples were incubated in 0.3% hydrogen
peroxidase for 15 min. to block endogenous peroxidase
activity, and incubated with Ki-67 monoclonal antibody
MIB1 (DAKO 1:50 dilution) for 60 min. Ki-67
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immunostaining was performed using a LSAB kit (DAKO)
and was demonstrated with a second-stage biotinconjugated antibody, with slides incubated for 30 min.,
followed by peroxidase-conjugated streptavidin for 30
min. All steps were performed at room temperature and
followed by washing in phosphate-buffered saline.
Peroxidase activity was detected with 3.3diaminobenzidine tetrahydrochloride in Tris-buffered
saline, pH 7.6 for 5 min. The slides were counterstained
with hemotoxylin.
The MIB1 labeling index was calculated as the number
of hepatocytes counted by two observers, counting at
least 1.000 cells. All the stained cells were considered
positive regardless staining type (homogenous, along the
nuclear membrane,etc.) and degree of staining.
Statistics
In order to see if there was a significant difference
between the HCC, MAC and control groups, one-way
ANOVA and post-ANOVA techniques were used. The
degree of differentiation in HCC tumors and Ki-67LI were
examined by Student’s t-test.

adenocarcinoma cases stained by Ki-67, there were 3
cases metastatic colon adenocarcinoma, 2 of metastatic
stomach adenocarcinoma cases, 2 of mucinous
adenocarcinoma originating from the gastrointestinal
system, 2 of metastatic pancreas adenocarcinoma, 2
metastatic breast carcinomas, and 2 cases of metastatic
adenocarcinoma originating from the lung. The primary
cause of 25 cases could not be found.
Of the 42 HCC cases, stained by Ki-67, 29 were
WDCT, 12 PDCT and 1 PLCT. Of these cases, the only
special-type PLCT HCC case was kept out of the statistical
analysis. WDCT cases were compared to PDCT in terms
of Ki-67LI. Ki-67LI was 32.06 ± 29.01 in the first group
(n=29) and in the second (n=12) 60.83 ± 28.74. The
results show a significant difference between the groups
(t = 2.96 p < 0.01)
Ki-67LI in HCC cases and some variables such as the
age of the patient, sex, location of tumor, diameter of
tumor, tumor invasiveness, AFP level, presence of HBsAg,
presence of cirrhosis and alcohol consumption were
analysed, but no significant relationship between the
variables could be found (p > 0.05).

Results
The mean of age 52.80 in HCC cases. The youngest
patient was 34, and the oldest 76; 90 % of the cases
were male. There was no relationship between sex and
Ki-67LI (P > 0.05). Ki-67LI was (mean ± standard
deviation) 53.75 ± 35.44 for female patients and 39.60
± 31.00 for male patients. Hepatitis B surface antigen
(HBsAg) was positive in 65% of HCC cases. Eight of the
cases were cirrhosis. There was chronic alcohol
consumption in 6 of the cases. The AFP level in serum
was high in all HHC cases. The smallest tumor in the cases
was 30 mm in diameter. In 11 cases the tumors were
located on the right lobe, on the left in 8 cases and
diffuses in 23. In 4 of the cases, there were local
recurrences within a year of surgery.
In HCC cases Ki-67 LI was 40.95 ± 31.25, in MAC
cases 24.86 ± 28.17, and in the control group 17.00 ±
21.66. Different types of staining were observed such as
diffuse, granular, along the perinuclear membrane etc.
The amount of staining among the cases was observed to
have changed. In some cases mostly cytoplasmic staining
was observed including reactive cells. Ki-67LI in HCC
cases was found significantly different than in the MAC
and reactive groups (p < 0.01). Among the 38 metastatic
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Discussion
There have been some difficulties in differentiating
HCC from reactive cells and metastatic tumors by FNAC.
There are some studies in the literature showing the
importance of proliferation indicators in differentiating
HCC from reactive cells and MAC (15). In order to do
that, proliferating cell nuclear antigen (PCNA) and P53
are usually used because of their ease of application in
tissue. Among these indicators, Ki-67 is a monoclonal
antibody, which was developed by Gerdes et al in 1983
(16,17). Although Ki-67 has some application difficulties
in tissue, liver specimens taken by FNAC are treated as
frozen and the application is carried at easily. Since FNAC
specimens are dried in the air, they are accepted as fresh
tissue, and do not therefore need to be treated with
tripsin in the microwave before applying the antibody. In
this way, money, time and effort can be saved. The other
techniques used to find out the growth ratio of tumors,
such as like tritiated thymidine, bromodeoxyuridine
incorporation and flow cytometry are difficult and
expensive. Ki-67 was applied in 100 cases and we aimed
to see if Ki-67LI can be used as an indicator of HCC and
wheather it is a differentiating feature of reactive cells
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group with 38 cases and the last was the control group
that comprised 20 liver specimens with no atypical cells.
Ki-67 was applied to all the groups. When the Ki-67LI
results were compared statistically significant difference
emerge between the HCC and the other two groups (p <
0.01).

Figure 1.

Ki-67 staining in HCC (Immunperoxidase x200).

Proliferating lesions in liver have been known in a
high spectrum (4). At one end of this spectrum, there is
a regenerative nodule, and at the other end there is
poorly differentiated HCC. In our study, 3 cases were
diagnosed as regenerative nodules in histopathologic
examinations. The level of labeling nucleus by Ki-67 in
these cases was lower than 25%.
In diagnosing HCC, there might be some confusion
between poorly differentiated HCC and MAC. In our study
there were 12 HCC cases in PDCT. In nine of these cases,
the level of Ki-67 staining was higher than 50%. In seven
of 38 MAC cases, the staining level was higher than 50%.
In histopathologic examination, one case that was
diagnosed as HCC had not been categorised as PDCT HCC
and MAC during cytologic examination. This case received
80.2% labeling nucleus by Ki-67 and was quiet
prominent.

Figure 2.

Ki-67 staining in HCC (Immunperoxidase x200).

Figure 3.

Ki-67 staining in MAC (Immunperoxidase x200).

and metastatic tumors. Another purpose of the study is
to determine the relationship between by Ki-67LI and
other prognostic factors of HCC cases.
There were three groups in this study. The first
consisted of 42 HCC cases, the second was the MAC

Many factors determine prognosis in HCC. Most of
the cases stained by Ki-67 were in the 5th and 6th
decades. The male/female ratio was 38/4. No significant
relationship between sex, age and Ki-67LI was found (p
> 0.05). In the literature, it is known that the prognosis
is better and the ratio of reoccurrence lower in women
than men (4,10). The reason: this is thought to be the
higher probability of tumor in the capsule and lower
tumor invasiveness in women (4). In addition some
clinical (18,19) and experimental studies (20) have
shown that if a patient is treated with androgens and
estrogens HCC may occur in that patient. However the
effect of tamoxifen and other estrogen receptor blockers
on the survival of hepatocellular carcinoma is
contraversial (21,22). In our study, in only one male case
was there a tumor in the capsule. We had no cases that
had been treated with hormones or used hormone
receptor blockers.
In HCC cases, the other two important prognostic
factors are the level of alpha-fetoprotein in serum (AFP)
and level of plasma des-γ-carboxy (8). In this study, AFP
levels were higher than usual in all cases. There was no
significant relationship between Ki-67LI and AFP levels (p
> 0.05).
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In HCC cases, although the tumors were of an
operable size it is known that prognosis was poor in the
postoperative period (23). The most important cause of
death in these cases is the relapse in the remaining liver.
The reason for this relapse is intrahepatic metastasis by
means of the portal vein. In our study, there was no
significant difference, in terms of getting staining by Ki67, between the HCC group and the group with
postoperative recurrences in the first year after operation
(6 cases) (p > 0.05).
In addition 65% of 42 HCC cases in this study were
suffering from cirrhosis. However the level of staining
was no different between the HCC with cirrhosis and HCC
without cirrhosis groups.
With the help of advanced display techniques, early
diagnosis of HCC is possible However, diagnosis of HCC
by means of display techniques has an effect on the
development of HCC in the early period, especially if
HBsAg is positive; and in cirrhosis cases. In Japan, a study
of this was carried out about this has been done on 28
cases in which tumor size was smaller than 20 mm (5).
These tumors are called “small HCC”. All these cases were
treated with alcohol injection. After this treatment, the 5year overall survival rates were varied between 60% and
70%. In our study the smallest tumor was 30 mm in
diameter. The size was between 40 and 60 mm in 20
cases, and greater than 60 mm in 21 cases. In 23 cases
the tumor was disseminated throughout the whole liver.

In the light of this, all the cases were considered to be
inoperable except for the small one that had been
operated on before. There was no significant relationship
between staining levels, diameter of tumor, and location
of tumor (p > 0.05).
There is a significant relationship between Ki-67LI and
the degree of differentiation tumor in HCC. In our study
42 cases were stained by Ki-67. Twenty-nine of these
were WDCT, 12 PDCT and 1 PLCT. Among these groups,
it was found that Ki-67LI was 32.06 ± 29.01 in the welldifferentiated group, while it was 60.83 ± 28.74 in the
poorly differentiated group. As a result, there was a
significant relationship between Ki-67LI and
differentiation degree (t = 2.96; p < 0.01). As a result,
1. Ki-67 can be easily applied in FNAC materials,
2. It can be used to support findings in
differentiating reactive hepatocyte and MAC from
HCC,
3. There is a significant relationship between
differentiation degree and Ki-67LI in HCC cases.
Correspondence author:
Ifl›n SOYUER
Erciyes Üniversitesi, Tip Fakültesi
Patoloji Anabilim Dal›,
Kayseri - TURKEY

References
1.

Ouchi K, Sugawara T, Ono H, Fujiya T,
et al. Mitotic index is the best predictive
factor for survival of patients with
resected hepatocellular carcinoma. Dig
Surg 17(1):42-8, 2000

2.

Suehiro T, Marsumata T, Itaska H et al:
Clinicopathologic
features
and
prognosis of resected hepatocellular
carcinomas of varied sizes with special
reference to proliferating cell nuclear
antigen. Cancer 76: 399-405, 1995

3.
4.

18

Chapel F, Guettier C, Chastang C et al.
Cancer 77: 864-871, 1996
Ojanguren I, Ar›za A, Llatjos M et al:
Proliferating cell nuclear antigen
expression in normal, regenerative and
neoplastic liver. Hum Pathol 24: 905908,1993

5.

6.

7.

Hino N, Higashi T, Nouso K et al:
Proliferating cell nuclear antigen and
Grade of malignancy in small
hepatocellular carcinoma - Evaluation in
US
guided
specimens-Hepatogastroenterology 44: 245-250, 1997
Souni Y, Virkajarvi N, Lehto VP et al:
Hepatocellular carcinomas with a high
proliferation index and a low degree of
apoptosis and necrosis are associated
with a shorthened survival. Br J Cancer
73: 1025-1030, 1996
Kitamoto M, Nakanishi T, Kira S et al:
The assessment of proliferating cell
nuclear antigen immunohistochemical
staining in small hepatocellular
carcinoma and its relationship to
histologic characteristics and prognosis.
Cancer 72: 1859-1865, 1993

8.

Soulier JP, Gozin D, LeFrere JJ: A new
method
to
assay
des-δcarboxyprothrombin: Result obtained in
75 cases of hepatocellular carcinoma.
Gastroenterology 91: 125-1262, 1986

9.

Ojanguren I, Jastella E, Lladjos M et al:
p53 immunoreaction in hapatocellular
carcinoma and its relationship to
etiologic factors. Acta Cytol 40: 11481153, 1996

10.

Farinati F, Cardin R, Derrico A et al:
Hepatocyte proliferative activity in
chronic liver damage as assessed by the
monoclonal antibody MIB1 Ki-67 in
archival material: the role of etiology,
disease activity, iron and lipid
peroxidation. Hepatology 23: 14681475, 1996

I. SOYUER, C. EK‹NC‹, M. KAYA, Y. GENÇ, K. BAHAR

11.

12.

Ng IOL, Ng M, Fan ST: Better survival in
women with resected hepatocellular
carcinoma is not related to tumor
proliferation or expression of hormone
receptors. The Am J Gastroenterol 92:
1355-1358, 1997
Kaita KD, Pettigrew N, Minuk GY:
Hepatic regeneration in humans with
various liver disease as assessed by Ki67 staining of formalin-fixed paraffin
embedded liver tissues. Liver 17:13-16,
1997

13.

Tiniakos DG, Brunt EM Proliferating cell
nuclear antigen and Ki-67 lebeling in
hepatocellular nodules: a comparative
study. Liver 19 (1): 58-68, 1999

14.

King KI, Hwang JJ, Chau Gy et al. Ki-67
expression as a prognostic marker in
patients with hepatocellular carcinoma.
J Gastrenterol Hepatol 13(3):273-9,
1998

15.

Adachi E, Hashimoto H, Tsuneyoshi M:
proliferating nuclear antigen in
hepatocellular carcinoma and small cell
liver dysplasia. Cancer 72: 2902-2909,
1993

16.

Brown DC, Gatter KC: Monoclonal
antibody
Ki-67:
its
use
in
histopathology. Histopathology 17:
489-503, 1990

17.

Gerdes J, Schwab U, Lemke H et al:
Production of a mouse monoclonal
antibody reactive with a human nuclear
antigen
associated
with
cell
proliferation. Int J Cancer 31: 13-20,
1983

18.

Ming CW, Chao WM, Zhang XH:
Primary hepatocellular carcinoma in
women of mainland China. Cancer 71:
2941-2945, 1993

19.

Shar S, Kew MC. Oral contraceptives
and hepatocellular carcinoma. Cancer
49: 407-410, 1982

20.

Coe JE, Ishak KG, Ross MJ: Estrogen
induction of hepatocellular carcinoma in
Armenian hamsters. Hepatology 11:
570-577, 1990

21.

Tan CK, Chow PK, Findlay M, Wong C,
Machin D. Use of tamoxifen in
hepatocellular carcinoma: a review and
paradigm. J Gastrenterol Hepatol 15(7):
725-729, 2000

22.

Liu CL, Fan ST, Ng IO, Lo CM, Poon RT,
Wong J. Treatment of advanced
hepatocellular
carcinoma
with
tamoxifen and the correlation with
expression of hormone receptors: a
prospective randomized study. Am J
Gastroenterol 1995(1):218-22, 2000.

23.

The Liver Cancer Study Group of Japan.
Predictive factors for long-term
prognosis after partial hepatectomy for
patients with hepatocellular carcinoma
in Japan. Cancer 74: 2772-2780,
1994.

19

